Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

PROPOSED AMENDMENTS AND ADOPTION OF THE SECOND AMENDED AND RESTATED ARTICLES OF ASSOCIATION

This announcement is made by Uni-Bio Science Group Limited ("**Company**", together with its subsidiaries as the "**Group**") pursuant to Rule 13.51(1) of the Rules ("**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited in relation to the proposed amendments to the second amended and restated articles of association of the Company currently in force ("**Second Amended and Restated Articles of Association**").

The board ("**Board**") of directors ("**Directors**") of the Company proposed to make certain amendments to the existing Articles of Association ("**Proposed Amendments**").

The major areas of the Proposed Amendments are set out below:

(i) bringing the existing Articles of Association in line with the latest regulatory requirements, including the relevant requirements of the Listing Rules in connection with hybrid meetings and electronic voting requirements, treasury shares and the electronic dissemination of corporate communications by listed issuers;

(ii) preparing for the uncertificated securities market regime; and

(iii) making certain other housekeeping changes that are consistent with such amendments and the Listing Rules;

and to adopt the second amended and restated Articles of Association incorporating and consolidating all the Proposed Amendments (the "**Second Amended and Restated Articles of Association**").

The Board is of the view that the Proposed Amendments are in the interests of the Company and its shareholders (the "**Shareholder(s)**") as a whole.

The Proposed Amendments are subject to the approval of the Shareholders by way of a special resolution at the forthcoming annual general meeting of the Company ("**Annual General Meeting**"), and will become effective upon the approval by the Shareholders at the Annual General Meeting.

A circular containing, among other matters, details of the Annual General Meeting and particulars relating to the Proposed Amendments and adoption of the second amended and restated Articles of Association, together with a notice of the Annual General Meeting, will be despatched to the Shareholders in due course.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 27 March 2026

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman), Mr. Zhao Zhi Gang (Chief executive) and Dr. Wen Yalei (Chief Operating Officer); two non-executive Directors, Mr. Yau Kwok Wing Tony and Ms. Zhang Qing; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.

* *For identification purpose only*